Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Debt: 2015-2024

Historic Total Debt for Seres Therapeutics (MCRB) over the last 4 years, with Jun 2024 value amounting to $102.5 million.

  • Seres Therapeutics' Total Debt rose 1.74% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 1.74%. This contributed to the annual value of $101.5 million for FY2023, which is 100.72% up from last year.
  • Per Seres Therapeutics' latest filing, its Total Debt stood at $102.5 million for Q2 2024, which was up 0.48% from $102.0 million recorded in Q1 2024.
  • Seres Therapeutics' 5-year Total Debt high stood at $102.5 million for Q2 2024, and its period low was $16.1 million during Q3 2021.
  • Moreover, its 3-year median value for Total Debt was $76.0 million (2023), whereas its average is $76.2 million.
  • In the last 5 years, Seres Therapeutics' Total Debt plummeted by 35.47% in 2021 and then skyrocketed by 215.55% in 2022.
  • Over the past 5 years, Seres Therapeutics' Total Debt (Quarterly) stood at $24.6 million in 2020, then climbed by 0.02% to $24.6 million in 2021, then spiked by 105.30% to $50.6 million in 2022, then surged by 100.72% to $101.5 million in 2023, then climbed by 1.74% to $102.5 million in 2024.
  • Its Total Debt was $102.5 million in Q2 2024, compared to $102.0 million in Q1 2024 and $101.5 million in Q4 2023.